An Open-label, Single-center Study to Assess the Pharmacokinetics of NKTR-118 in Patients With Impaired Hepatic Function and Subjects With Normal Hepatic Function Following Administration of a Single Dose of 25mg NKTR-118
Phase of Trial: Phase I
Latest Information Update: 01 Jan 2016
At a glance
- Drugs Naloxegol (Primary)
- Indications Pain
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 13 Jan 2012 Actual initiation date (1 Nov 2011 ) added as reported by ClinicalTrials.gov.
- 13 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Aug 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.